In a model of LPS-induced AKI, treatment with dexmedetomidine, a selective α2 adrenal receptor (α2-AR) agonist, induced the expression of HO-1 and NQO-1 via the GSK-3β/Nrf2 signaling pathway, decreasing AKI pathological features [141,143]. The gene discussed is ADORA2A; the disease is acute kidney injury.